Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial.

ABSTRACT:

Background & aims

Thiazolidinedione ligands for the gamma subtype of peroxisome proliferator-activated receptors (PPARgamma), widely used to treat type 2 diabetes mellitus, have been proposed as novel therapies for ulcerative colitis (UC).

Methods

This multicenter, randomized, double-blind, placebo-controlled clinical trial compared the efficacy of rosiglitazone (Avandia; GlaxoSmithKline, Philadelphia, PA) 4 mg orally twice daily vs placebo twice daily for 12 weeks in 105 patients with mild to moderately active UC. Disease activity was measured with the Mayo score. The primary end point was clinical response (>/=2-point reduction) at week 12. Clinical remission (Mayo score ResultsAfter 12 weeks

SUBMITTER: Lewis JD 

PROVIDER: S-EPMC2276587 | biostudies-literature | 2008 Mar

REPOSITORIES: biostudies-literature